These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22896634)

  • 21. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer.
    Kim HS; Choo YS; Koo T; Bang S; Oh TY; Wen J; Song SY
    Immunol Lett; 2006 Mar; 103(2):142-8. PubMed ID: 16313973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
    Bersani F; Taulli R; Accornero P; Morotti A; Miretti S; Crepaldi T; Ponzetto C
    Eur J Cancer; 2008 Apr; 44(6):876-84. PubMed ID: 18342500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
    Labussiere M; Pinel S; Delfortrie S; Plenat F; Chastagner P
    Oncol Rep; 2008 Nov; 20(5):1283-7. PubMed ID: 18949434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
    Straube C; Wehner R; Wendisch M; Bornhäuser M; Bachmann M; Rieber EP; Schmitz M
    Leukemia; 2007 Jul; 21(7):1464-71. PubMed ID: 17495970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
    Kao C; Chao A; Tsai CL; Lin CY; Chuang WC; Chen HW; Yen TC; Wang TH; Lai CH; Wang HS
    Cell Death Dis; 2013 Feb; 4(2):e512. PubMed ID: 23449448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
    Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
    Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model.
    Mudnakudu Nagaraju KK; Babina M; Worm M
    Exp Dermatol; 2013 Nov; 22(11):742-7. PubMed ID: 24118387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
    Shen J; Song G; An M; Li X; Wu N; Ruan K; Hu J; Hu R
    Biomaterials; 2014 Jan; 35(1):316-26. PubMed ID: 24125776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
    Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
    Blood; 2009 Jun; 113(24):6120-7. PubMed ID: 19202127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
    Perrone G; Hideshima T; Ikeda H; Okawa Y; Calabrese E; Gorgun G; Santo L; Cirstea D; Raje N; Chauhan D; Baccarani M; Cavo M; Anderson KC
    Leukemia; 2009 Sep; 23(9):1679-86. PubMed ID: 19369963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.
    Brüning A; Burger P; Vogel M; Rahmeh M; Friese K; Lenhard M; Burges A
    Invest New Drugs; 2009 Dec; 27(6):543-51. PubMed ID: 19039521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model.
    Huang Z; Peng S; Knoff J; Lee SY; Yang B; Wu TC; Hung CF
    J Biomed Sci; 2015 Jan; 22(1):7. PubMed ID: 25591912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.